Value of molecular targets and genome-targeted cancer therapies FDA-approved, 2015-2022

被引：0
|
作者：
Tibau, A. [1 ]
Hwang, T. J. [2 ]
Consolacion, M. [3 ]
Avorn, J. [4 ]
Kesselheim, A. [4 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
[2] Brigham & Womens Hosp, Div Urol Surg, Boston, TX USA
[3] Princess Margaret Canc Ctr, Med Oncol Dept, Toronto, ON, Canada
[4] Brigham & Womens Hosp, PORTAL Program Regulat Therapeut & Law, Pharmacoepidemiol & Pharmacoecomon Div, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2657
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1703P
引用
收藏
页码：S930 / S930
页数：1
相关论文
共 49 条
  • [31] Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies
    Rahman, Muntajin
    Akter, Khadija
    Ahmed, Kazi Rejvee
    Fahim, Md. Maharub Hossain
    Aktary, Nahida
    Park, Moon Nyeo
    Shin, Sang-Won
    Kim, Bonglee
    CANCERS, 2024, 16 (16)
  • [32] The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones
    Workman, P
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (Suppl 1) : S45 - S56
  • [33] The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones
    Paul Workman
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 45 - 56
  • [34] ANTITUMOR ACTIVITY OF SUNITINIB VERSUS OTHER FDA-APPROVED TARGETED CANCER AGENTS AGAINST METASTATIC RENAL CELL CARCINOMA IN THE FIRST-LINE SETTING
    Rampersaud, Edward N.
    Birkhauser, Frederic D.
    Logan, Joshua E.
    Sonn, Geoffrey
    Chan, Yvonne
    Pouliot, Frederic
    Wang, Xiaoyan
    Li, Gang
    Kabbinavar, Fairooz
    Pantuck, Allan J.
    Belldegrun, Arie S.
    JOURNAL OF UROLOGY, 2012, 187 (04): : E808 - E808
  • [35] FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I
    Wang, Ying
    Nan, Xiang
    Duan, Yanping
    Wang, Qiuxu
    Liang, Zhigang
    Yin, Hanrong
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 111
  • [36] Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine)
    De Francesco, Ernestina Marianna
    Ozsvari, Bela
    Sotgia, Federica
    Lisanti, Michael P.
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [37] Multi-targeted molecular docking, drug-likeness and ADMET studies of derivatives of few quinoline- and acridine-based FDA-approved drugs for anti-breast cancer activity
    Sing, Lai Cong
    Roy, Anitha
    Hui, Lok Yong
    Mun, Chan Sook
    Rajak, Harish
    Karunakaran, Rohini
    Ravichandran, Veerasamy
    STRUCTURAL CHEMISTRY, 2022, 33 (03) : 649 - 669
  • [38] Multi-targeted molecular docking, drug-likeness and ADMET studies of derivatives of few quinoline- and acridine-based FDA-approved drugs for anti-breast cancer activity
    Lai Cong Sing
    Anitha Roy
    Lok Yong Hui
    Chan Sook Mun
    Harish Rajak
    Rohini Karunakaran
    Veerasamy Ravichandran
    Structural Chemistry, 2022, 33 : 649 - 669
  • [39] Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs
    Wenying Angela Liu
    Li Yu
    Peter N. Morcos
    Francois Mercier
    Barbara J. Brennan
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 1015 - 1027
  • [40] Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs
    Liu, Wenying Angela
    Yu, Li
    Morcos, Peter N.
    Mercier, Francois
    Brennan, Barbara J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (06) : 1015 - 1027
12345